Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

Biofluid Based Biomarker Professional Interest Area

Research output: Contribution to journalShort survey

93 Scopus citations

Abstract

The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.

Original languageEnglish (US)
Pages (from-to)45-58
Number of pages14
JournalAlzheimer's and Dementia
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2017

    Fingerprint

Keywords

  • Alzheimer's disease
  • Biomarker
  • Blood
  • Cerebrospinal fluid
  • Context of use
  • Diagnosis
  • Diagnosis
  • Imaging

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Geriatrics and Gerontology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this